ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigating Efficacy and Safety of Once-weekly NNC0195-0092 (Somapacitan) Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02616562
Recruitment Status : Active, not recruiting
First Posted : November 30, 2015
Last Update Posted : May 25, 2018
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S

Brief Summary:

This trial is conducted globally. The aim of the trial is to investigate efficacy and safety of once-weekly NNC0195-0092 (somapacitan) treatment compared to daily growth hormone treatment (Norditropin® FlexPro®) in growth hormone treatment naïve pre-pubertal children with growth hormone deficiency.

The main trial period will consist of 26 weeks of treatment, followed by a 26 week extension period and a 104 weeks safety extension trial period.


Condition or disease Intervention/treatment Phase
Growth Hormone Disorder Growth Hormone Deficiency in Children Drug: somapacitan Drug: Norditropin® FlexPro® pen Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Trial Investigating Efficacy and Safety of Once-weekly NNC0195-0092 (Somapacitan) Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency naïve Pre-pubertal Children With Growth Hormone Deficiency
Actual Study Start Date : March 23, 2016
Actual Primary Completion Date : March 1, 2018
Estimated Study Completion Date : August 31, 2020


Arm Intervention/treatment
Experimental: Blinded NNC0195-0092 (somapacitan) (0.04 mg/kg/week) Drug: somapacitan
Administered subcutaneously (s.c., under the skin) once-weekly.
Other Name: NNC0195-0092

Experimental: Blinded NNC0195-0092 (somapacitan) (0.08 mg/kg/week) Drug: somapacitan
Administered subcutaneously (s.c., under the skin) once-weekly.
Other Name: NNC0195-0092

Experimental: Blinded NNC0195-0092 (somapacitan) (0.16 mg/kg/week) Drug: somapacitan
Administered subcutaneously (s.c., under the skin) once-weekly.
Other Name: NNC0195-0092

Active Comparator: Open labelled daily Norditropin® (0.034 mg/kg/day) Drug: Norditropin® FlexPro® pen
Administered subcutaneously (s.c., under the skin) once daily.




Primary Outcome Measures :
  1. Height velocity (HV) (cm/year) during the first 26 weeks of treatment, measured as standing height with stadiometer [ Time Frame: Week 0-26 ]

Secondary Outcome Measures :
  1. Change in height standard deviation score (SDS) [ Time Frame: Week 26, 52, 104, and 156 ]
  2. Change in HV (height velocity) SDS [ Time Frame: Week 26, 52, 104 and week 156 ]
  3. Incidence of adverse events, including injection site reactions [ Time Frame: week 26, 52, 104, 156 and 157 ]
  4. Occurrence of anti-NNC0195-0092 (somapacitan) and anti-hGH antibodies [ Time Frame: week 26, 52, 104, 156 and 157 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Months to 10 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Boys: Tanner stage 1 for pubic hair and testis volume below 4 ml , age at least 2 years and 26 weeks and below or equal to 10.0 years at screening
  • Girls: Tanner stage 1 for breast development (no palpable glandular breast tissue) and pubic hair, age at least 2 years and 26 weeks and below or equal to 9.0 years at screening
  • Confirmed diagnosis of GHD (growth hormone deficiency) within 12 months prior to screening as determined by two different GH (growth hormone) stimulation tests, defined as a peak GH level of below or equal to 7.0 ng/ml. For children with three or more pituitary hormone deficiencies only one GH stimulation test is needed
  • No prior exposure to GH therapy and/or IGF-I (insulin-like growth factor I) treatment
  • Height of at least 2.0 standard deviations below the mean height for chronological age (CA) and gender according to the standards of Centers for Disease Control and Prevention 2-20 years: Girls/Boys stature-for-age and weight-for-age percentiles CDC at screening
  • Annualized height velocity (HV) below the 25th percentile for CA (chronological age) and gender or below -0.7 SD (standard deviation) score for CA and sex, according to the standards of Prader calculated over a time span of minimum 6 months and maximum 18 months

Exclusion Criteria:

  • Any clinically significant abnormality likely to affect growth or the ability to evaluate
  • growth with standing measurements: Chromosomal aneuploidy and significant gene mutations causing medical "syndromes" with short stature, including but not limited to Turner syndrome, Laron syndrome, Noonan syndrome, or absence of GH receptors. Congenital abnormalities (causing skeletal abnormalities), including but not limited to Russell-Silver Syndrome, skeletal dysplasias. Significant spinal abnormalities including but not limited to scoliosis, kyphosis and spina bifida variants
  • Children born small for gestational age (SGA - birth weight and/or birth length below-2 SD for gestational age)
  • Concomitant administration of other treatments that may have an effect on growth, including but not limited to methylphenidate for treatment of attention deficit hyperactivity disorder (ADHD)
  • Prior history or presence of malignancy and/or intracranial tumour

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02616562


  Show 56 Study Locations
Sponsors and Collaborators
Novo Nordisk A/S

Additional Information:
Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT02616562     History of Changes
Other Study ID Numbers: NN8640-4172
2015-000531-32 ( EudraCT Number )
U1111-1166-7062 ( Other Identifier: WHO )
First Posted: November 30, 2015    Key Record Dates
Last Update Posted: May 25, 2018
Last Verified: May 2018

Additional relevant MeSH terms:
Dwarfism, Pituitary
Dwarfism
Endocrine System Diseases
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Bone Diseases, Endocrine
Hypopituitarism
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs